At #MLS_DC25 in Washington, a session on ALK TKIs showed how the field has moved from crizotinib in 2013 to ensartinib in 2025.

Choosing first-line therapy depends on efficacy, safety, and patient factors - there’s no one-size-fits-all in ALK+ #LungCancer

#LCSM